8.76
+0.9(+11.45%)
Currency In USD
| Previous Close | 7.86 |
| Open | 7.9 |
| Day High | 8.76 |
| Day Low | 7.88 |
| 52-Week High | 12.34 |
| 52-Week Low | 2.24 |
| Volume | 968,297 |
| Average Volume | 992,241 |
| Market Cap | 409.11M |
| PE | -2.34 |
| EPS | -3.75 |
| Moving Average 50 Days | 9.75 |
| Moving Average 200 Days | 6.58 |
| Change | 0.9 |
If you invested $1000 in 4D Molecular Therapeutics, Inc. (FDMT) since IPO date, it would be worth $216.3 as of January 14, 2026 at a share price of $8.76. Whereas If you bought $1000 worth of 4D Molecular Therapeutics, Inc. (FDMT) shares 5 years ago, it would be worth $190.43 as of January 14, 2026 at a share price of $8.76.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
4DMT Provides Company Update and Anticipated Development Milestones for 2026
GlobeNewswire Inc.
Jan 07, 2026 1:00 PM GMT
Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, with 381 patients randomized or approved to randomize as of January 6, 20264D-150 PRISM wet AMD 2-year Pha
4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease
GlobeNewswire Inc.
Dec 17, 2025 12:00 PM GMT
Clinically meaningful lung function activity, measured by ppFEV1 and LCI2.5, with follow-up through 1 year at dose selected for Phase 2 Durable CFTR transgene expression within target therapeutic range with follow-up through at least 1 year Data supp
4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 08, 2025 1:00 PM GMT
EMERYVILLE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatmen